FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL					
OMB Number: 3235-0104					
Estimated average burden					
hours per response:	0.5				

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Shafer Bradford J	2. Date of Event Requiring Statem (Month/Day/Year) 09/01/2014	ent 7	3. Issuer Name and Ticker or Trading Symbol Theravance Biopharma, Inc. [ TBPH ]					
(Last) (First) (Middle) C/O THERAVANCE BIOPHARMA US, INC.			. Relationship of Reporting Perso Check all applicable) Director Officer (give title	10% Owner Other (specify below)		5. If Amendment, Date of Original Filed (Month/Day/Year)		
901 GATEWAY BOULEVARD			X Officer (give title below) Sr VP, Gen. Counsel,			6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person		
(Street) SOUTH SAN FRANCISCO CA 94080							y More than One	
(City) (State) (Zip)								
	Table I - Non-	-Derivativ	e Securities Beneficiall	y Owned				
1. Title of Security (Instr. 4)	Table I - Non-	2. /	/e Securities Beneficiall Amount of Securities Perficially Owned (Instr. 4)	3. Ownersh Form: Direct or Indirect (Instr. 5)	cṫ (D)   (Ins	lature of Indirect str. 5)	t Beneficial Ownership	
	Table I - Non-	2. /	Amount of Securities	3. Ownersh Form: Direct	cṫ (D)   (Ins		t Beneficial Ownership	
Title of Security (Instr. 4)  Ordinary Shares	Table II - De	2. A Be	Amount of Securities neficially Owned (Instr. 4)	3. Ownersh Form: Direct or Indirect (Instr. 5)	ct (D) (Ins		t Beneficial Ownership	
Title of Security (Instr. 4)  Ordinary Shares	Table II - De	erivative s, warran	Amount of Securities neficially Owned (Instr. 4)  26,384  Securities Beneficially O	3. Ownersh Form: Director Indirect (Instr. 5)  D  Dwned Securitie ties	ct (D) (Ins	5. Ownership	6. Nature of Indirect Beneficial Ownership (Instr. 5)	

**Explanation of Responses:** 

Bradford J. Shafer

09/10/2014

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints Heather Shane, Brett Grimaud and Elizabeth Webb with full power of substitution, as the undersigned's true and lawful attorneys-in-fact to:

- (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% stockholder of Theravance Biopharma, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorneys-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorneys-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorneys-in-fact may approve in such attorneys-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneys-in-fact, or such attorneys-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 10th day of September, 2014.

/s/ Bradford J. Shafer